Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase 1 3Phase 1/2 2

Status

Completed 3Recruiting 2Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Lung Neoplasms 3Small Cell Lung Carcinoma 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Completed × amrubicin × Clear all
NCT02481830 2023-07-27

CheckMate331

Bristol-Myers Squibb

Phase 3 Completed
569 enrolled 13 charts
Thoracic

Lung Neoplasms

NCT00547651 2019-11-06

AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Celgene

Phase 3 Completed
637 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT00660504 2014-07-18

Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer

Sumitomo Pharma (Suzhou) Co., Ltd.

Phase 3 Completed
300 enrolled 10 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡